Monika Pazgan−Simon

2.0k total citations
52 papers, 500 citations indexed

About

Monika Pazgan−Simon is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Monika Pazgan−Simon has authored 52 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Epidemiology, 20 papers in Hepatology and 11 papers in Infectious Diseases. Recurrent topics in Monika Pazgan−Simon's work include Liver Disease Diagnosis and Treatment (18 papers), Hepatitis C virus research (11 papers) and COVID-19 Clinical Research Studies (8 papers). Monika Pazgan−Simon is often cited by papers focused on Liver Disease Diagnosis and Treatment (18 papers), Hepatitis C virus research (11 papers) and COVID-19 Clinical Research Studies (8 papers). Monika Pazgan−Simon collaborates with scholars based in Poland, Germany and Spain. Monika Pazgan−Simon's co-authors include Krzysztof Simon, Jolanta Zuwała−Jagiełło, Maria Warwas, Michał Kukla, Katarzyna Kotfis, Igor Łoniewski, Luis F. Lara, Anastasios Koulaouzidis, Wojciech Marlicz and Dominika Maciejewska and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Monika Pazgan−Simon

49 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Monika Pazgan−Simon Poland 14 193 152 136 69 60 52 500
Mengzhen Dong China 9 210 1.1× 169 1.1× 77 0.6× 101 1.5× 80 1.3× 21 542
Andrea R. Mospan United States 10 161 0.8× 100 0.7× 71 0.5× 46 0.7× 49 0.8× 19 411
Kai Dai China 10 91 0.5× 207 1.4× 37 0.3× 72 1.0× 70 1.2× 19 484
Maria Grazia Marazzi Italy 16 336 1.7× 78 0.5× 295 2.2× 67 1.0× 13 0.2× 29 801
Weihua Cai China 12 87 0.5× 116 0.8× 52 0.4× 195 2.8× 52 0.9× 27 417
Zhenwei Yang China 13 81 0.4× 201 1.3× 37 0.3× 208 3.0× 135 2.3× 35 618
Shaorui Hao China 11 149 0.8× 42 0.3× 207 1.5× 118 1.7× 60 1.0× 18 487
Xiaolan Lu China 13 140 0.7× 113 0.7× 55 0.4× 130 1.9× 7 0.1× 33 469
Khalid Farooqui India 10 507 2.6× 113 0.7× 90 0.7× 165 2.4× 51 0.8× 29 952
Jordan Hindson Denmark 7 49 0.3× 176 1.2× 23 0.2× 124 1.8× 41 0.7× 88 484

Countries citing papers authored by Monika Pazgan−Simon

Since Specialization
Citations

This map shows the geographic impact of Monika Pazgan−Simon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monika Pazgan−Simon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monika Pazgan−Simon more than expected).

Fields of papers citing papers by Monika Pazgan−Simon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monika Pazgan−Simon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monika Pazgan−Simon. The network helps show where Monika Pazgan−Simon may publish in the future.

Co-authorship network of co-authors of Monika Pazgan−Simon

This figure shows the co-authorship network connecting the top 25 collaborators of Monika Pazgan−Simon. A scholar is included among the top collaborators of Monika Pazgan−Simon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monika Pazgan−Simon. Monika Pazgan−Simon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chan, Stephen L., Zhenggang Ren, Yuxian Bai, et al.. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.. Journal of Clinical Oncology. 42(16_suppl). 4110–4110. 16 indexed citations
2.
3.
Pazgan−Simon, Monika, Jerzy Jaroszewicz, Krzysztof Simon, et al.. (2023). Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland. Journal of Personalized Medicine. 13(7). 1111–1111. 3 indexed citations
4.
Pazgan−Simon, Monika, et al.. (2022). Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma. Pharmacological Reports. 74(6). 1306–1314. 4 indexed citations
5.
Rzymski, Piotr, Monika Pazgan−Simon, Anna Moniuszko‐Malinowska, et al.. (2022). Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. Vaccines. 10(4). 557–557. 20 indexed citations
6.
Gkika, Eleni, Anca - Ligia Grosu, T. Macarulla Mercadé, et al.. (2022). Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study. Cancers. 14(6). 1568–1568. 20 indexed citations
7.
8.
Rzymski, Piotr, Monika Pazgan−Simon, Krzysztof Simon, et al.. (2021). Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. Vaccines. 9(7). 781–781. 27 indexed citations
9.
Gkika, Eleni, Anca - Ligia Grosu, Teresa Macarulla, et al.. (2021). O-16 HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma. Annals of Oncology. 32. S225–S225. 3 indexed citations
10.
Kukla, Michał, Karolina Skonieczna‐Żydecka, Katarzyna Kotfis, et al.. (2020). COVID-19, MERS and SARS with Concomitant Liver Injury—Systematic Review of the Existing Literature. Journal of Clinical Medicine. 9(5). 1420–1420. 81 indexed citations
11.
Pazgan−Simon, Monika, et al.. (2020). Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC). PLoS ONE. 15(1). e0227459–e0227459. 16 indexed citations
12.
Pazgan−Simon, Monika, et al.. (2020). Accurate prediction of significant liver fibrosis using the Pentra score model in patients with chronic hepatitis C. Polskie Archiwum Medycyny Wewnętrznej. 130(2). 112–120. 3 indexed citations
13.
Pazgan−Simon, Monika, et al.. (2020). Gastrointestinal symptoms as the first, atypical indication of SARS-CoV-2 infection. Polskie Archiwum Medycyny Wewnętrznej. 130(4). 338–339. 10 indexed citations
14.
Pazgan−Simon, Monika, et al.. (2019). Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C. BioMed Research International. 2019. 1–11. 11 indexed citations
15.
Simon, Krzysztof, et al.. (2016). The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin. Clinical and Experimental Hepatology. 4(4). 155–160. 2 indexed citations
16.
Zuwała−Jagiełło, Jolanta, Krzysztof Simon, & Monika Pazgan−Simon. (2015). Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report. Clinical and Experimental Hepatology. 3(3). 105–111. 6 indexed citations
17.
Zwolińska, Katarzyna, Brygida Knysz, Monika Pazgan−Simon, et al.. (2012). Protective Effect of CCR5-Δ32 Against HIV Infection by the Heterosexual Mode of Transmission in a Polish Population. AIDS Research and Human Retroviruses. 29(1). 54–60. 7 indexed citations
18.
Piasecki, E, Brygida Knysz, Katarzyna Zwolińska, et al.. (2010). Inhibition of Vesicular Stomatitis Virus Replication in the Course of HIV Infection in Patients with Different Stages of Immunodeficiency. Viral Immunology. 23(6). 567–576. 4 indexed citations
19.
Zuwała−Jagiełło, Jolanta, et al.. (2008). [Fluorescence of age in serum in detecting liver cirrhosis and hepatocellular carcinoma among patients with anti-HCV antibodies].. PubMed. 62(2). 393–400. 4 indexed citations
20.
Zuwała−Jagiełło, Jolanta, et al.. (2006). Advanced Glycation Endproducts in Serum of Patients with Chronic Hepatitis and Liver Cirrhosis. Advances in Clinical and Experimental Medicine. 15(2). 259–264. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mengzhen Dong Breakdown of academic impact, for papers by Andrea R. Mospan Breakdown of academic impact, for papers by Kai Dai Breakdown of academic impact, for papers by Maria Grazia Marazzi Breakdown of academic impact, for papers by Weihua Cai Breakdown of academic impact, for papers by Zhenwei Yang Breakdown of academic impact, for papers by Shaorui Hao Breakdown of academic impact, for papers by Xiaolan Lu Breakdown of academic impact, for papers by Khalid Farooqui Breakdown of academic impact, for papers by Jordan Hindson
Rankless by CCL
2026